To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Omega emerges as direct secondary player
The firm, led by former AlpInvest life sciences specialist Otello Stampacchia, has agreed to acquire six ‘tail-end’ portfolio investments from Atlas Venture in a secondary transaction.
